Please login to the form below

Not currently logged in
Email:
Password:

ado-trastuzumab emtansine

This page shows the latest ado-trastuzumab emtansine news and features for those working in and with pharma, biotech and healthcare.

UK approval for Seagen’s oral HER2 inhibitor Tukysa

UK approval for Seagen’s oral HER2 inhibitor Tukysa

In 2019, Seagen announced that it had initiated another trial of Tukysa – the HER2CLIMB-02 study – that will compare Tukysa to placebo in combination with Kadcyla (ado-trastuzumab emtansine) in

Latest news

More from news
Approximately 1 fully matching, plus 17 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Don’t limit diversity to just representation in clinical trials
What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...
InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....

Infographics